drugset
drugset / Trial / NCT03613727

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

NCT03613727 ↗

Phase 2 Completed 61 enrolled Virginia Commonwealth University
NaSingle-groupOpen-labelTreatment

Summary

This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.

Timeline

Start
2018-10-01
Primary completion
2022-10-06
Completion
2022-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 16.7 mg/kg Intravenous
Subject Vitamin C Other / unclassified 500 mg Intravenous

Indications

lymphoid leukemia monocytic leukemia myelodysplastic syndrome myeloid leukemia